These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25176263)

  • 41. [Use of cerebrolysin in the treatment of prolonged extrapyramidal complications of neuroleptic therapy].
    Kontsevoĭ VA; Medvedev AV; Andrusenko MP; Zvenigorodskaia IuV; Sheshenin VS
    Zh Nevrol Psikhiatr Im S S Korsakova; 1997; 97(6):39-44. PubMed ID: 11517474
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The influence of cerebrolysin on the efficiency of subsequent therapy with amiridine++ in Alzheimer's disease patients (neuropsychological investigation)].
    Roshchina IF; Kolykhalov IV; Selezneva ND; Zharikov GA; Gerasimov NP; Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(12):43-6. PubMed ID: 10629930
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Efficiency of cerebrolysin in the diabetic polyneuropathy in patients with insulin-dependency diabetes mellitus].
    Bogdanov EI; Sakovets TG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2):35-9. PubMed ID: 21350421
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.
    Panisset M; Gauthier S; Moessler H; Windisch M;
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1089-104. PubMed ID: 12111446
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effect of vinpocetin on the hemorheologic parameters in patients with chronic cerebrovascular disease].
    Szapáry L; Horváth B; Alexy T; Márton Z; Késmárky G; Szóts M; Nagy F; Czopf J; Tóth K
    Orv Hetil; 2003 May; 144(20):973-8. PubMed ID: 12830727
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cerebrolysin and its emerging clinical applications in psychiatry.
    Kapoor S
    Aust N Z J Psychiatry; 2013 Jul; 47(7):685. PubMed ID: 23405015
    [No Abstract]   [Full Text] [Related]  

  • 47. Neuroprotective therapy.
    Grotta JC; Hickenbottom S
    Rev Neurol (Paris); 1999; 155(9):644-6. PubMed ID: 10528342
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neuroprotective effect of a new taurinamide derivative--Taurepar.
    Krylova IB; Bulion VV; Gavrovskaya LK; Selina EN; Kuznetzova NN; Sapronov NS
    Adv Exp Med Biol; 2006; 583():543-50. PubMed ID: 17153643
    [No Abstract]   [Full Text] [Related]  

  • 49. [Effects of acetylsalicylic acid and diquertin on platelet aggregation and hemorheological parameters in rats with cerebral ischemia].
    Plotnikova MB; Iamkin aV; Aliev OI; Tiukavkina NA
    Eksp Klin Farmakol; 2005; 68(2):33-5. PubMed ID: 15934364
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The experience with endolumbar application of cerebrolysin in hemispheric ischemic stroke].
    Vilenskiĭ BS; Odinak MM; Shirokov EA; Vozniuk IA; Semenova GM; Grinevich TV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(11):31-4. PubMed ID: 11247183
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [A comparison of a neuroprotective effects of hypoxic postconditioning and cerebrolysin in the experimental model].
    Rybnikova EA; Vorob'ev MG; Pivina SG; Samoĭlov MO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2):54-8. PubMed ID: 23528584
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Pharmacological approaches to the therapy of Alzheimer's disease].
    Gavrilova SI
    Vestn Ross Akad Med Nauk; 2006; (9-10):30-4. PubMed ID: 17111921
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuroprotective therapy.
    Hickenbottom SL; Grotta J
    Semin Neurol; 1998; 18(4):485-92. PubMed ID: 9932619
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Neuroprotective effects of magnesium on cerebral ischemia and cerebral contusion].
    Enomoto T; Noda Y; Nabeshima T
    Clin Calcium; 2004 Aug; 14(8):60-4. PubMed ID: 15577098
    [TBL] [Abstract][Full Text] [Related]  

  • 55. VESTIBULAR DYSFUNCTIONS IN CHRONIC BRAIN ISCHEMIA IN THE POST COVID PERIOD.
    Stoyanov AN; Mashchenko SS; Kalashnikov VI; Vastyanov RS; Pulyk AR; Andreeva TO; Kolesnik OO
    Wiad Lek; 2023; 76(3):591-596. PubMed ID: 37057785
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hemorheology in cerebral ischemia.
    Kowal P
    Neurol Neurochir Pol; 1996; 30 Suppl 2():7-11. PubMed ID: 9100237
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The multimodal strategy for the neuroprotection in stroke: results of the Russian multicenter clinical-epidemiological program SOKOL].
    Tabeeva GR; Azimova IuE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(12 Pt 2):20-30. PubMed ID: 23388602
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Physiological effects and brain protection by hypothermia and cerebrolysin after moderate forebrain ischemia in rats.
    Schwab M; Bauer R; Zwiener U
    Exp Toxicol Pathol; 1997 Feb; 49(1-2):105-16. PubMed ID: 9085084
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The effect of cerebrolysin on cognitive functions in childhood autism and in Asperger syndrome].
    Krasnoperova MG; Bashina VM; Skvortsov IA; Simashkova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(6):15-8. PubMed ID: 12872620
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study.
    Muresanu DF; Alvarez XA; Moessler H; Novak PH; Stan A; Buzoianu A; Bajenaru O; Popescu BO
    J Neurol Sci; 2010 Dec; 299(1-2):179-83. PubMed ID: 20923712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.